21st Century Oncology LLC

1. Seattle Genetics, Inc. $231,972 11 payments
2. Pfizer Inc. $82,250 14 payments
3. Helsinn Healthcare SA $16,438 5 payments
4. Janssen Research & Development, LLC $11,769 2 payments
5. Bayer HealthCare Pharmaceuticals Inc. $5,908 4 payments
6. Mirati Therapeutics, Inc. $1,350 1 payment
7. Astellas Pharma Global Development $1,145 4 payments
8. Taiho Oncology, Inc. $900 1 payment
9. Argenx US, Inc. $500 1 payment

1. Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors $224,472 10 payments
2. A Randomized Phase II Trial of Salvage Radiotherapy With Standard VS Enhanced Androgen Deprivation Therapy With Enzalutamide in Patients With Postprostatectomy Psa Recurrences With Aggressive Disease Features $62,750 12 payments
3. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer NSCLC $11,250 1 payment
4. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $9,750 1 payment
5. A Phase 1B2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukinnktr214 With Or Without Talazoparib Or Enzalutamide in Participants With Locally Advanced Or Metastatic Solid Tumors $9,750 1 payment
6. Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study $7,631 1 payment
7. Open-Label Phase 2 Study of Ladiratuzumab Vedotin LV for Unresectable Locally Advanced or Metastatic Solid Tumors $7,500 1 payment
8. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) $5,188 4 payments
9. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy $4,138 1 payment
10. Clinical Trial Pase IV (Post Marketing) (Bayer Product or TA) $3,000 2 payments

1. Non-patient care $1,350 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.